Related Experiment Video
Updated: May 13, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Identification of novel inhibitors targeting EGFR L858R/T790M/C797S against NSCLC by molecular docking, MD
Chaochun Wei1, Cuicui Ji1, Keli Zong1
1College of Chemistry and Life Science, Beijing University of Technology, Beijing, 100124, PR China.
Abstract:
The resistance of growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC), especially against the EGFR L858R/T790M/C797S mutations, remains an ongoing challenge. In this study, we screened a total of 2.05 million compounds from the ChEMBL database through virtual screening, identifying five promising candidates with high binding affinities and favourable ADMET properties. These candidates were further evaluated through molecular dynamics (MD) simulations, revealing more restricted conformational changes and enhanced stability compared to Osimertinib. Protein-ligand interaction analyses highlighted a broader range of stabilizing interactions in the binding domain. Additionally, the binding free energies of the compounds showed that compounds 1-5 ranged from -34.95 to -45.54 kcal/mol, which were lower compared to Osimertinib (-34.49 kcal/mol), suggesting a stronger binding affinity. Subsequently, density functional theory (DFT) calculations provided further insights into the electronic properties of the compounds, which were essential for understanding the compounds' reactivity and potential interactions with the target protein. In conclusion, the five identified compounds exhibit promising drug-like properties and may serve as lead candidates for the development of new treatments targeting EGFR L858R/T790M/C797S resistance mutations in NSCLC.
Insights
Researchers identified five novel compounds effective against EGFR-TKI resistance in non-small cell lung cancer (NSCLC). These candidates show stronger binding and stability than Osimertinib, offering new hope for treating resistant EGFR mutations.
Area of Science:
- Medicinal Chemistry
- Computational Drug Discovery
- Oncology
Background:
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are crucial for non-small cell lung cancer (NSCLC) treatment.
- Acquired resistance, particularly to mutations like EGFR L858R/T790M/C797S, limits the long-term efficacy of current therapies.
Purpose of the Study:
- To identify novel drug candidates overcoming EGFR-TKI resistance in NSCLC.
- To evaluate potential compounds for improved binding affinity, stability, and drug-like properties against resistant EGFR mutations.
Main Methods:
- Virtual screening of over 2 million compounds from the ChEMBL database.
- Molecular dynamics (MD) simulations and protein-ligand interaction analyses.
- Density functional theory (DFT) calculations for electronic property assessment.
Main Results:
- Five promising compounds were identified with high binding affinities and favorable ADMET profiles.
- MD simulations indicated enhanced stability and restricted conformational changes compared to Osimertinib.
- Calculated binding free energies (-34.95 to -45.54 kcal/mol) suggest stronger binding than Osimertinib (-34.49 kcal/mol).
Conclusions:
- The identified compounds demonstrate significant potential as lead candidates for NSCLC treatment.
- These novel agents may offer a therapeutic strategy against EGFR L858R/T790M/C797S resistance mutations.
- Further development could lead to new therapies for patients with resistant NSCLC.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
